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Effect of Monthly, High-Dose, Long-Term Vitamin D Supplementation
on Central Blood Pressure Parameters: A Randomized Controlled Trial
Substudy
John D. Sluyter, PhD; Carlos A. Camargo, Jr, MD, DrPH; Alistair W. Stewart, BSc; Debbie Waayer, MEd; Carlene M. M. Lawes, MBChB, PhD;
Les Toop, MBChB, MD; Kay-Tee Khaw, MBBChir, MSc; Simon A. McG. Thom, MBBS, MD; Bernhard Hametner, PhD; Siegfried
Wassertheurer, PhD; Kim H. Parker, PhD; Alun D. Hughes, MBBS, PhD; Robert Scragg, MBBS, PhD
Background-—The effects of monthly, high-dose, long-term (≥1-year) vitamin D supplementation on central blood pressure (BP)
parameters are unknown.
Methods and Results-—A total of 517 adults (58% male, aged 50–84 years) were recruited into a double-blinded, placebo-controlled
trial substudy and randomized to receive, for 1.1 years (median; range: 0.9–1.5 years), either (1) vitamin D3 200 000 IU (initial dose)
followed 1 month later by monthly 100 000-IU doses (n=256) or (2) placebo monthly (n=261). At baseline (n=517) and follow-up
(n=380), suprasystolic oscillometry was undertaken, yielding aortic BP waveforms and hemodynamic parameters. Mean
deseasonalized 25-hydroxyvitamin D increased from 66 nmol/L (SD: 24) at baseline to 122 nmol/L (SD: 42) at follow-up in the
vitamin D group, with no change in the placebo group. Despite small, nonsigniﬁcant changes in hemodynamic parameters in the total
sample (primary outcome), we observed consistently favorable changes among the 150 participants with vitamin D deﬁciency
(<50 nmol/L) at baseline. In this subgroup, mean changes in the vitamin D group (n=71) versus placebo group (n=79) were 5.3
mm Hg (95% conﬁdence interval [CI],11.8 to 1.3) for brachial systolic BP (P=0.11),2.8 mm Hg (95% CI,6.2 to 0.7) for brachial
diastolic BP (P=0.12),7.5 mm Hg (95% CI,14.4 to0.6) for aortic systolic BP (P=0.03),5.7 mm Hg (95% CI,10.8 to0.6) for
augmentation index (P=0.03), 0.3 m/s (95% CI, 0.6 to 0.1) for pulse wave velocity (P=0.02), 8.6 mm Hg (95% CI, 15.4 to
1.9) for peak reservoir pressure (P=0.01), and 3.6 mm Hg (95% CI, 6.3 to 0.8) for backward pressure amplitude (P=0.01).
Conclusions-—Monthly, high-dose, 1-year vitamin D supplementation lowered central BP parameters among adults with vitamin D
deﬁciency but not in the total sample.
Clinical Trial Registration-—URL: http://www.anzctr.org.au. Unique identiﬁer: ACTRN12611000402943. ( J Am Heart Assoc.
2017;6:e006802. DOI: 10.1161/JAHA.117.006802.)
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S ystematic reviews of cohort studies have found thatserum 25-hyroxyvitamin D (25(OH)D) concentration cor-
relates inversely with hypertension and cardiovascular
events.1,2 Because these associations were observational, it
is not clear whether they are attributed to effects of vitamin D
or to confounding factors such as physical activity and
obesity. To investigate the causality and reversibility of low
vitamin D and cardiovascular-related end points, randomized
controlled trials (RCTs) are required.
Several RCTs have examined the inﬂuence of vitamin D
supplementation on brachial blood pressure (BP) and gener-
ally do not indicate a beneﬁcial lowering effect.3,4 In
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comparison, fewer RCTs have evaluated effects on variables
derived from central BP waveforms.5 This is important
because such measures, which include aortic systolic BP
(SBP), augmentation index (AIx), pulse wave velocity (PWV),
backward pressure amplitude, and excess pressure integral,
predict cardiovascular events independently of or more
strongly than brachial BP.6–9 Moreover, RCTs show that
antihypertensive medications have differential effects on
these parameters despite similar inﬂuences on brachial
BP,10–12 indicating that the latter has limited usefulness in
capturing changes in central BP parameters. Because these
ﬁndings suggest that measurements from central BP wave-
forms are different than those from brachial BP, it might be
difﬁcult to extrapolate results of vitamin D trials based on
brachial BP to effects on central BP parameters.
Most prior RCTs of vitamin D supplementation on central BP
parameters have reported no beneﬁcial impact.5 These studies,
however, were mostly short (≤6 months) and, consequently,
might not have been long enough to ﬁnd signiﬁcant effects. Only
a few RCTs have been long term (≥1 year),13–16 but the daily
dose equivalent (dose divided by days between each dose) of
vitamin D used in these studies was submaximal (<1650 IU/
day) and thus could both be suboptimal and underestimate
possible effects at higher dosing regimens (eg, daily dose
equivalent >3000 IU/day). Furthermore, the central BP param-
eters included in these studies were limited to SBP, diastolic BP
(DBP), AIx, or PWV13,17–21; they did not include other measures
such as those derived from wave separation or reservoir wave
analyses, which capture different aspects of arterial function.8,9
Consequently, in an RCT, we examined the effect of long-term,
high-dose vitamin D supplementation on awide range of central
BP parameters (and brachial BP for comparison).
Methods
Participants
This study was a prespeciﬁed analysis of a subsample of
participants in the ViDA (Vitamin D Assessment) study who
underwent safety-related measurements for 1 year. The
ViDA study was a randomized, double-blinded, placebo-
controlled trial of the effect of vitamin D supplementation
on health outcomes, with cardiovascular disease as the
primary end point. Inclusion criteria were men and women
aged 50 to 84 years and resident in Auckland, New Zealand.
Exclusion criteria were (1) diagnosis of a terminal illness and/
or in hospice care; (2) intending to leave New Zealand during
the follow-up period; (3) taking vitamin D supplements
(including cod liver oil) of >600 IU daily if aged 50 to
70 years or >800 IU daily if aged 71 to 84 years; (4) history
of renal stones, hypercalcemia, or medical conditions that can
cause hypercalcemia; and (5) baseline serum calcium
>2.50 mmol/L. Screening and baseline measurements took
place between 2011 and 2012, with 5110 being randomized
by computer to receive either vitamin D or placebo. Random
assignment to one of the 2 treatment groups was made with
random block sizes of 8, 10, or 12, within ethnic and 5-year
age groups. The randomization process was supervised by the
study biostatistician (A.W.S.) to ensure that staff who
collected the data were blinded to allocation. Ethics approval
was provided by the New Zealand Multiregion Ethics
Committee (MEC/09/08/082). Written, informed consent
was obtained from each participant. This study was registered
with the Australian New Zealand Clinical Trials Registry
(ACTRN12611000402943). Full details of the study design,
including a ﬂowchart showing the number of people screened
and excluded in the main ViDA study before the randomization
of all 5110 participants, have been published elsewhere.22
Vitamin D Intervention
Vitamin D3 (2.5 mg [100 000 IU]) or placebo softgel oral
capsules, sourced from Tishcon Corp, were mailed to
participants’ homes. Two capsules were sent in the ﬁrst
Clinical Perspective
What Is New?
• Our randomized controlled trial of vitamin D supplementa-
tion used a unique combination of monthly, high-dose
vitamin D dosing for 1 year in a population-based sample
and assessed novel central blood pressure (BP) parameters
not measured in previous trials.
• To our knowledge, this study is the ﬁrst to show that
monthly vitamin D supplementation lowers central BP
parameters in vitamin D–deﬁcient people.
• Our novel use of factor analysis showed that these
reductions are attributed to 2 unique effects of vitamin D:
decreases in maximum BP and pulse rate–related augmen-
tation of the pressure waveform.
What Are the Clinical Implications?
• Because BP-lowering effects were limited to vitamin D–
deﬁcient people, future trials should focus on this group.
• Because vitamin D lowered central BP parameters but had
nonsigniﬁcant effects on brachial BP, future vitamin D
assessments should include measuring central BP param-
eters to capture efﬁcacy rather than rely solely on brachial
BP.
• Although the lowering of central BP parameters in vitamin
D–deﬁcient people was sizeable and presumably is beneﬁ-
cial, randomized controlled trials are needed to conﬁrm
whether these effects translate into improvements in
cardiovascular morbidity and mortality.
DOI: 10.1161/JAHA.117.006802 Journal of the American Heart Association 2
Vitamin D and Central Blood Pressure Parameters Sluyter et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
mailing after randomization (ie, a 200 000-IU bolus or placebo
at the start of the intervention period), followed by a 2.5-mg
(100 000-IU) capsule of vitamin D3 (or placebo) monthly
throughout the remainder of the follow-up period.
Non–Arterial Function Measures
All measurements were carried out by trained staff using a
standardized protocol. Questionnaires administered by inter-
viewers were used to collect data on age, sex, ethnicity
(deﬁned by self-identiﬁcation), smoking, alcohol consumption,
sun exposure, physical activity, diabetes mellitus, and use of
vitamin D supplements and antihypertensive medications. The
national medicine dispensing database was used to determine
details of antihypertensive medications received at baseline
and follow-up, even for those who did not return for
measurements. Without shoes and in light clothing, height
was measured with a stadiometer to the nearest 0.1 cm, and
weight was measured with digital scales to the nearest
0.1 kg. Body mass index was calculated as body weight (kg)
divided by height (m)2.
Blood samples were collected at baseline and at 6 and
12 months of follow-up, and plasma aliquots were stored
frozen at 80°C. Serum 25(OH)D (combining D2 and D3)
concentration was measured in these aliquots (baseline and
follow-up samples were measured in the same batch for each
participant) by liquid chromatography–tandem mass spec-
trometry (ABSciex API 4000) at a laboratory participating in
the DEQAS (Vitamin D External Quality Assessment Scheme)
program (http://www.deqas.org).
Arterial Function Measurements
Arterial function measurements were made at baseline and at
1-year follow-up. After 15 minutes of rest and while sitting,
brachial BP (1 mm Hg) was measured 3 times with an
Omron T9P oscillometric device (Omron Healthcare) above
the cubital fossa of the left arm. The mean of the 2 closest
measurements was used for analyses. Hypertensive partici-
pants were deﬁned as those who had brachial SBP
≥140 mm Hg or brachial DBP ≥90 mm Hg and/or who were
receiving antihypertensive medications (determined from the
questionnaires and the national medicine dispensing data-
base).
Suprasystolic oscillometry was carried out using a BP+
device (Uscom [formerly known as the R6.5 cardiovascular
monitor; Pulsecor]), with an appropriately sized cuff posi-
tioned over the left upper arm. The BP+ device has been
shown (1) to yield central SBPs that are highly correlated with
those assessed by catheter measurement at the ascending
aorta or aortic arch23 and (2) to measure central SBP with
good intratest and intertest reliability.24 To improve the
quality of the waveforms used in analyses, we decided a priori
to exclude readings with a signal-to-noise ratio <3 dB (below
acceptable).
In addition to aortic SBP and DBP, several parameters that
predict cardiovascular events independently of brachial BP
were calculated from the aortic pressure waveform.6,8,9,25–29
AIx (%),6 an index of arterial stiffness and wave reﬂection,30
was calculated from the aortic pressure waveform using
custom-written Matlab software (Mathworks). Aortic PWV7
was calculated from validated algorithms.25,26 Aortic pressure
was separated into reservoir and excess components using
custom-written Matlab software. Reservoir pressure was
calculated from pressure measurements only, as described
elsewhere.8 Peak reservoir pressure was calculated as the
maximum of the reservoir pressure waveform.27 Excess
pressure was calculated as measured pressure minus reser-
voir pressure.8 The integral of the excess and reservoir
pressure waveforms (area under these) over the cardiac cycle
was used to calculate excess pressure integral and reservoir
pressure integral, respectively. The former measures pressure
associated with excess ventricular work.8 Aortic pressure was
separated into forward- and backward-traveling pressure
waves using wave separation analysis.27 Their amplitudes—
forward pressure amplitude and backward pressure ampli-
tude9,29—were then calculated by a technique that yields
values similar to those obtained using true aortic ﬂow waves
measured by Doppler ultrasound.31 Wave intensity analysis
was used to calculate wave reﬂection index.28
Statistical Analyses
Data were analyzed using SAS version 9.3 (SAS Institute).
Baseline group differences in characteristics and differential
missingness of data were assessed with ANOVA (for contin-
uous variables) and the chi-square test (for categorical
variables). We examined changes from baseline to follow-up
in (1) the number of antihypertensive drugs, with the paired t
test and Wilcoxon signed-rank test, and (2) the proportion
receiving antihypertensive medication, with the McNemar
test. Treatment group differences at follow-up were assessed
with Monte Carlo estimates of the Fisher exact test (for the
number of antihypertensive drugs) and the chi-square test (for
the proportion on antihypertensive medication). Variables that
were positively skewed (excess pressure integral and wave
reﬂection index) were log-transformed. Factor analysis with
varimax rotation was applied to BP parameters to reduce
these to fewer, uncorrelated factors that represent distinct
attributes that explain a high fraction of the variability in the
original variables. These factors were extracted by the method
of principal components, and only principal components that
accounted for more than the variance of 1 variable (eigen-
value >1) were retained and used in subsequent analyses.
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Factor loadings (correlations between factors and original
variables) of ≥0.3 were considered signiﬁcant.32 On an
intention-to-treat basis, general linear mixed models were
used to assess the effect of vitamin D supplementation on 25
(OH)D and BP parameters (adjusted for age, sex, and
ethnicity) with repeated time incorporated using an unstruc-
tured correlation structure, using PROC MIXED. This analysis
method handles missing data by ﬁtting a statistical model
over all available observations without introducing bias.
Speciﬁcally, to test whether the change from baseline differed
across the treatment groups, we examined the interaction
between treatment group and time.
Deseasonalized (season-adjusted) baseline 25(OH)D levels
were calculated for each participant from the midpoint
between the estimated maximum and minimum 25(OH)D
levels over a calendar year from their individual measured
baseline 25(OH)D and date of blood collection, using a
sinusoidal model with parameters derived from baseline
values for all participants in the main ViDA study.33 Vitamin D
deﬁciency was deﬁned as having a deseasonalized 25(OH)D
<50 nmol/L.33
In addition to performing analyses in the total sample, we
decided a priori to perform subgroup analyses among vitamin
D–deﬁcient persons. This is because nonlinear relationships
between 25(OH)D concentration and health outcomes, includ-
ing mortality34,35 and CVD,2 suggest that adverse effects
associated with low vitamin D status are greatest in vitamin
D–deﬁcient persons, indicating that vitamin D supplementa-
tion could be more effective in such individuals. In further
prespeciﬁed analyses, we examined 3-way interactions among
vitamin D deﬁciency (present or absent), treatment group, and
time so as to test whether the effects of vitamin D were
different in those with and without vitamin D deﬁciency and
supplemented this with a subgroup analysis among people
without vitamin D deﬁciency.
Because of the inﬂuence of antihypertensive medications
on BP, we examined 3-way interactions between antihyper-
tensive treatment (presence or absence), treatment group
(vitamin D or placebo), and time so as to test whether the
effects of vitamin D were different in those who received and
did not receive antihypertensive therapy. The ViDA study was
originally powered to detect a clinically relevant reduction in
cardiovascular events (primary outcome), as described else-
where.22 For the current substudy, with 90% power and at the
5% signiﬁcance level (2-tailed), the detectable differences in
standard deviations of BP parameters were 0.3 in the total
sample and 0.5 in the vitamin D–deﬁcient sample. Scatter
plots ﬁtted with smoothed curves36 (using PROC LOESS)
revealed in the vitamin D group that change in central BP
parameters appeared to vary with baseline deseasonalized 25
(OH) up to 65 nmol/L in several cases and remained
relatively constant beyond this threshold. Consequently, we
used Pearson correlation coefﬁcients to summarize these
associations in people with baseline deseasonalized 25(OH)D
<65 nmol/L. Correlations between changes in deseasonal-
ized 25(OH)D and changes in BP parameters were also
summarized with Pearson correlation coefﬁcients. Robust
estimates (95% conﬁdence intervals [CIs]) of these correlation
coefﬁcients were calculated using 1000 bootstrap samples.
Statistical signiﬁcance was set at P<0.05 (2-sided). No P value
correction was applied to account for multiple hypothesis
tests, as we did not want to miss any important ﬁndings.37
Results
Figure 1 shows the study ﬂow diagram. Of the 5110
participants randomized in the main ViDA study, 518 (10%)
were randomly selected and invited to partake in the
current substudy. Of these, 1 withdrew consent (analysis of
data disallowed) and was not included in any further
analysis. Of the remaining 517, a complete set of both
baseline and 1-year follow-up measurements was available
for 380 and missing for 137 (26%): 124 did not attend the
follow-up interview (declined to attend, could not attend,
could not be contacted, or moved overseas), and 13 had
arterial BP waveform data that were poor quality (signal-to-
noise ratio <3 dB) or unobtainable (unable to get a
reading). Most (57%) of 137 missing follow-up cases were
due to people indicating at their baseline assessment that
they did not wish to return for a follow-up interview, ruling
out the possibility of bias from loss to follow-up (missing-
ness due to changes in BP-related health) in this group. All
of the abovementioned 517 participants were included in
the intention-to-treat analysis. Altogether, the percentage of
the intention-to-treat sample that had missing follow-up
data did not differ across the 2 treatment groups (P=0.38).
Furthermore, this missingness was unrelated to baseline BP
parameters such as brachial SBP (P=0.87).
The regimens of antihypertensive medications (categorized
by their classes) by treatment group at baseline and follow-up
are shown in Tables S1 (total sample) and S2 (vitamin D–
deﬁcient sample). In the total sample, neither the number of
drugs nor the proportion receiving antihypertensive medica-
tion changed from baseline to follow-up in either the vitamin D
or the placebo group (P values varying from 0.31 to 0.68).
This was also true in the vitamin D–deﬁcient sample (P values
of 0.09–0.80). Furthermore, in each sample, neither the
number of drugs nor the proportion receiving antihypertensive
medication differed across treatment groups at follow-up (P
values of 0.14–0.64).
Of the entire intention-to-treat sample (total sample), 256
received vitamin D and 261 received placebo. Among vitamin
D–deﬁcient people, 71 and 79 received vitamin D and
placebo, respectively. Baseline characteristics of these
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participants by treatment group are given in Table 1. In the
total sample, the mean age was 65.0 years (range: 50–
84 years), 56% were male, and 75% were of European or other
ethnicity (96% of whom had European ancestry). Just under
half had smoked cigarettes or used tobacco (with most being
former smokers), 14% reported <1 h/day of sun exposure,
11% took vitamin D supplements (within the study eligibility
criteria) and nearly two thirds were hypertensive. The mean
concentrations of observed and deseasonalized 25(OH)D
were 63 nmol/L (SD: 25) and 66 nmol/L (SD: 24), respec-
tively, with 29% of people having a deseasonalized 25(OH)D of
<50 nmol/L (indicative of vitamin D deﬁciency). In compar-
ison, the vitamin D–deﬁcient sample—with mean observed
and deseasonalized 25(OH)D concentrations of 36 nmol/L
(SD: 10) and 39 nmol/L (SD: 8), respectively—had a greater
percentage of non-Europeans (49%). The time period between
Randomized
n=5110
Allocated to
vitamin D
n=2558
Allocated to
placebo
n=2552
Randomly
invited for
1-year follow-up
n=256
Randomly
invited for 1-
year follow-up
n=262
Included in
primary
intention-to-treat
analysis
n=256
Complete set of
baseline &
follow-up data
n=193
Declined, could
not attend,
uncontactable
or moved
overseas
n=57
Poor-quality or
unattainable BP
data
n=6
Complete set of
baseline &
follow-up data
n=187
Declined, could
not attend,
uncontactable
or moved
overseas
n=67
Poor-quality or
unattainable BP
data
n=7
Included in
primary
intention-to-treat
analysis
n=261
Withdrew
consent
n=1
Withdrew
consent
n=0
Figure 1. Flowchart showing the number of randomized participants who were excluded and those with
complete sets of both baseline and 1-year follow-up measurements. BP indicates blood pressure.
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randomization and follow-up averaged 1.1 years (both mean
and median) and ranged from 0.9 to 1.5 years.
Figure 2 shows the deseasonalized 25(OH)D concentration
at baseline and follow-up visits by treatment group. The
change from baseline in the vitamin D group with respect to
placebo at 6- and 12-month follow-up, respectively, was 51
nmol/L (95% CI, 44–57) and 58 nmol/L (95% CI, 51–64),
respectively, for the total sample and 56 nmol/L (95% CI, 45–
66) and 58 nmol/L (95% CI, 48–68) nmol/L, for the vitamin D-
deﬁcient sample (all P<0.001).
Table 2 shows BP waveform parameters at baseline and
follow-up by intervention group in the total sample (n=517).
The effects of vitamin D compared with placebo on the
parameters were in the positive direction for pulse rate, AIx,
Table 1. Baseline Comparison of Participants Across Treatment Groups
Variable
Total Sample Vitamin D-Deﬁcient Sample*
Vitamin D (n=256) Placebo (n=261) Vitamin D (n=71) Placebo (n=79)
Age, y† 64.58.3 65.58.8 63.38.6 64.79.1
Male sex, % 60 52 56 48
Ethnicity
European/other, % 73 78 49 52
Maori, % 7 7 14 8
Pacific, % 12 8 17 22
South Asian, % 8 7 20 19
Smoking
Nonsmoker, % 53 50 56 58
Former smoker, % 37 42 34 38
Current smoker, % 9 8 10 4
Alcohol consumption
Nondrinker, % 8 7 12 13
Former drinker, % 11 8 17 18
Current drinker, % 82 86 71 70
Sun exposure, h/d
<1, % 14 13 20 19
1–2, % 53 52 48 62
>2, % 32 35 32 19
Vigorous physical activity, h/wk
None, % 39 39 55 49
1–2, % 25 27 26 26
>2, % 37 35 20 26
Diabetes mellitus, % 2 3 3 6
Vitamin D supplements, % 11 11 4 6
Hypertension, % 66 63 65 77
Antihypertensive medication, % 44 39 48 56
Body mass index, kg/m2† 28.85.2 28.65.2 30.86.9 29.76.2
25-hydroxyvitamin D
Observed† 62.124.7 63.124.6 35.210.2 36.59.9
Deseasonalized† 65.823.8 66.024.1 38.18.6 38.98.0
Deseasonalized <50 nmol/L, % 28 30 100 100
Time from randomization to follow-up, d† 40129 40230 39832 40132
*Those with deseasonalized 25-hydroxyvitamin D <50 nmol/L.
†Values are meanSD.
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and loge(wave reﬂection index) and consistently in the
negative direction for the remaining variables; however,
observed changes were small and not statistically signiﬁcant.
In addition, these effects were not moderated by antihyper-
tensive therapy (P values varying from 0.29 to 0.96).
These analyses were repeated in participants with vitamin D
deﬁciency at baseline (n=150; Table 3). Pulse rate change did
not signiﬁcantly differ across the 2 treatment groups (P=0.05).
With respect to placebo, vitamin D reduced aortic SBP
(7.5 mm Hg), AIx (5.7%), PWV (0.3 m/s), peak reservoir
pressure (8.6 mm Hg), reservoir pressure integral
(9.8 mm Hg/s), backward pressure amplitude (3.6
mm Hg), and forward pressure amplitude (3.3 mm Hg; all
P<0.05). The effects (vitamin D minus placebo) on the
remaining parameters, including brachial SBP and DBP, were
consistently in the negative direction, although not statistically
signiﬁcant (P>0.05). Antihypertensive treatment did not mod-
erate any of these effects (P values of 0.15–0.92). Factor
analysis of changes (follow-up minus baseline) in these
parameters yielded 4 factors (Table S3), but only factors 1
and 2 differed across the 2 intervention groups (Table S4) and,
as evident from their loadings (Table S3), predominantly
accounted for the signiﬁcant, between-group changes in
individual BP parameters (Table 3). In other words, compared
with placebo, vitamin D reduced factors 1 (representing
maximum BP) and 2 (representing slower pulse rate and raised
augmentation of the pressure waveform; Table S4).
Further analysis showed that vitamin D (with respect to
placebo) caused greater reduction of AIx (P=0.009), PWV
(P=0.0498), peak reservoir pressure (P=0.01), reservoir
pressure integral (P=0.01), backward pressure amplitude
(P=0.01), and loge(wave reﬂection index) (P=0.047) in
participants with vitamin D deﬁciency than in those without.
As a reﬂection of this, the effects of vitamin D (versus placebo)
in those with vitamin D deﬁciency (Table 3) were larger than in
those without (Table S5).
Correlations between deseasonalized 25(OH)D (baseline
and change) and change in BP parameters in the vitamin D
group are shown in Table S6. At <65 nmol/L, baseline
deseasonalized 25(OH)D was positively correlated with
changes in aortic SBP, AIx, PWV, peak reservoir pressure,
and forward pressure amplitude (r=0.18–0.24), indicating
larger reductions with decreasing 25(OH)D. Among those with
vitamin D deﬁciency (deseasonalized 25(OH)D <50 nmol/L)
at baseline, 25(OH)D change was negatively correlated
(r=0.23 to 0.31) with change in several parameters,
which included all of those shown in Table 3 that were
reduced by vitamin D supplementation.
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Figure 2. Bar graphs showing deseasonalized 25(OH)D concentration (nmol/L) at baseline and follow-up
(6 and 12 mo) in the vitamin D (gray bars) and placebo (white bars) groups. The bars represent meanSD.
DOI: 10.1161/JAHA.117.006802 Journal of the American Heart Association 7
Vitamin D and Central Blood Pressure Parameters Sluyter et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Discussion
This randomized, double-blinded, placebo-controlled trial
demonstrated that monthly high-dose (daily dose equivalent
>3300-IU/day) vitamin D supplementation over an average
period of 1.1 years had little effect on central and brachial BP
parameters in the total sample. However, among people with
vitamin D deﬁciency at baseline, it resulted in presumably
beneﬁcial reductions in several central BP parameters that, as
evident from the factor analysis results, are attributed to 2
unique effects of vitamin D: decreases in maximum BP and
pulse rate–related augmentation of the pressure waveform.
The absence of antihypertensive effects in the total sample
(73% without vitamin D deﬁciency) concurs with several
previous vitamin D trials that similarly comprised mostly
participants without vitamin D deﬁciency.5 We extended these
past trial ﬁndings, as our study used a unique combination of
monthly high-dose vitamin D dosing for 1 year in a popula-
tion-based sample and assessed novel parameters not
measured in previous trials (eg, excess pressure integral
and backward pressure amplitude). For instance, only a few
prior RCTs used monthly ≥100-kIU dosing (as our study did)
but for not more than 6 months.17,21,38
To our knowledge, this study is the ﬁrst to show that
monthly vitamin D supplementation reduces central BP
variables in persons with vitamin D deﬁciency. Two RCTs of
vitamin D–deﬁcient participants found beneﬁcial effects of
vitamin D supplementation on AIx but not on PWV.39,40
Compared with our study, these RCTs had shorter follow-up
periods (<6 months) and different dosing regimens (daily39 or
a single intramuscular dose40) and did not measure other
parameters (eg, peak reservoir pressure) that were modiﬁed
beneﬁcially by vitamin D in our study. In contrast, other RCTs
in vitamin D–deﬁcient participants found that vitamin D
supplementation did not result in improvements in any central
BP parameters: PWV, AIx, SBP, DBP, or pulse pressure.14,41–43
Possible reasons for this discrepancy are that most of these
studies were smaller (n≤62) and of shorter duration
(<6 months),41–43 whereas the remaining study administered
half the vitamin D dose (50 000 IU monthly) that we used.14
Because we observed beneﬁcial effects in vitamin D–deﬁcient
participants but not in the total sample, and several param-
eters decreased more in participants with vitamin D deﬁ-
ciency than in those without, this implies that vitamin D trials
in people with normal vitamin D levels may underestimate
effects among those with vitamin D deﬁciency. Consequently,
future trials should focus on vitamin D-deﬁcient persons.
A mechanism by which vitamin D may lower BP is through
impact on the renin–angiotensin system,44 indicating that it
could be blunted by antihypertensive medications; however,
this may not be the only mechanism, as antihypertensive
therapy did not moderate the vitamin D effects in our study.
Antihypertensive effects could also occur through improve-
ment in endothelial function and a reduction in vascular
Table 2. Arterial Function Measures at Baseline and Follow-up (Adjusted for Age, Sex, and Ethnicity) by Treatment Group in the
Total Sample (N=517)
Variable
Mean (SD)
Change From Baseline, Vitamin D
Minus PlaceboVitamin D Group (n=256) Placebo Group (n=261)
Baseline Follow-up Baseline Follow-up Mean (95% CI) P Value
Pulse rate, beats/min 63.0 (10.0) 65.7 (9.5) 63.9 (11.0) 65.7 (11.8) 0.9 (0.7 to 2.6) 0.27
Brachial SBP, mm Hg 137.7 (18.4) 128.9 (16.1) 137.7 (16.8) 131.0 (18.9) 2.1 (5.2 to 0.9) 0.17
Brachial DBP, mm Hg 78.4 (10.6) 73.7 (9.9) 78.7 (9.7) 74.8 (9.9) 0.8 (2.5 to 0.8) 0.32
Aortic SBP, mm Hg 140.1 (18.4) 131.1 (16.2) 139.7 (17.8) 132.9 (20.2) 2.2 (5.4 to 0.9) 0.17
Aortic DBP, mm Hg 72.0 (6.6) 69.5 (6.1) 72.2 (6.0) 70.2 (6.1) 0.5 (1.5 to 0.6) 0.41
Augmentation index, % 30.0 (12.1) 27.0 (11.2) 29.9 (13.1) 26.8 (12.6) 0.0 (2.4 to 2.5) 0.98
Pulse wave velocity, m/s 9.3 (1.7) 9.2 (1.6) 9.3 (1.7) 9.3 (1.9) 0.1 (0.2 to 0.0) 0.18
Peak reservoir pressure, mm Hg 124.3 (17.8) 116.5 (15.1) 124.2 (16.4) 118.4 (18.5) 2.0 (5.1 to 1.1) 0.21
Peak excess pressure, mm Hg 28.5 (8.3) 25.8 (7.9) 28.1 (8.5) 26.1 (8.3) 0.7 (2.5 to 1.0) 0.40
Reservoir pressure integral, mm Hg/s 92.1 (18.3) 83.0 (16.7) 91.7 (21.0) 85.4 (21.5) 2.8 (6.1 to 0.5) 0.10
Loge(excess pressure integral, mm Hg/s) 1.57 (0.38) 1.40 (0.42) 1.54 (0.43) 1.39 (0.43) 0.02 (0.11 to 0.06) 0.59
Backward pressure amplitude, mm Hg 28.6 (7.3) 25.3 (6.3) 28.5 (7.5) 25.9 (8.3) 0.8 (2.0 to 0.5) 0.25
Forward pressure amplitude, mm Hg 40.0 (8.4) 36.8 (7.9) 39.5 (8.5) 37.5 (9.6) 1.2 (2.7 to 0.4) 0.14
Loge(wave reflection index), 910
2 120.6 (35.0) 124.5 (28.8) 118.1 (35.9) 125.7 (35.7) 3.7 (4.3 to 11.8) 0.36
CI indicates conﬁdence interval; DBP, diastolic blood pressure; SBP, systolic blood pressure.
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tone.44 We showed that this could be associated with a
decrease in arterial stiffness, as PWV was lowered by vitamin
D (Table 3). Furthermore, we propose that this reduction in
vascular tone could improve impedance matching at arterial
pressure wave reﬂection sites, thereby reducing the magni-
tude of reﬂected arterial pressure waves, as has been
suggested to occur with antihypertensive vasodilator
drugs.11,45 This wave reﬂection effect is supported by vitamin
D lowering backward pressure amplitude (Table 3).
In the vitamin D–deﬁcient sample, the magnitude of each
signiﬁcant intervention effect as a percentage of the average BP
parameter value for a person was sizeable. For example, the
intervention effect for backward pressure amplitude
(3.6 mm Hg) as a percentage of the mean baseline value
for this parameter in the vitamin D group (28.7 mm Hg;
Table 3) was 13%. Importantly, these effects would translate
into clinically meaningful reductions in cardiovascular risk.6–
9,27,29 Given that, for example, a 10% increase in central AIx is
associated with a relative risk for cardiovascular outcomes of
1.318,6 a 5.7% decrease (net vitamin D effect; Table 3) would
correspond to a theoretical relative risk reduction of up to 17%.
These beneﬁcial risk reductions would be partly cumulative
because the factor analysis revealed that the BP parameter
changes reﬂect 2 unique effects rather than a single one.
In the main ViDA study, vitamin D supplementation had no
apparent effect on cardiovascular events.46 This does not
necessarily mean that the reductions in central BP parameters
observed in the current substudy (Table 3) do not translate
into improvements in cardiovascular morbidity and mortality.
It may be that any improvements (eg, ≤17% relative risk
reduction; mentioned in the previous paragraph) were smaller
than those that could be detected in the main ViDA study
(21% reduction at up to 80% power46).
Although effects on brachial BP were in the negative
(lowering) direction, they were non-signiﬁcant, unlike those
for central BP parameters (Table 3). This suggests that
vitamin D trials based on brachial BP3 underestimate effects
on central BP parameters. Consequently, future trials should
include measuring central BP parameters to capture efﬁcacy
rather than rely solely on brachial BP.
Our study was population-based, which enhances the
generalizability of our ﬁndings. As for the limitations, the
missingness of the intention-to-treat sample (Figure 1) raises
the possibility that selection bias could inﬂuence the study
ﬁndings. As reported, however, this missingness did not differ
across the treatment groups and was unrelated to BP
parameters. A longer follow-up period may have enabled us
to gain better insight into the long-term effects of the
intervention. Although larger than prior RCTs of vitamin D and
central BP parameters,13,17–21 our statistical power was
limited (especially in the vitamin D–deﬁcient sample), which
may explain the lack of statistical signiﬁcance of some
treatment effects. Finally, the use of multiple outcomes
increases the likelihood that at least some of our signiﬁcant
Table 3. Arterial Function Measures at Baseline and Follow-up (Adjusted for Age, Sex, and Ethnicity) by Treatment Group Among
Those With Baseline Vitamin D Deﬁciency (Deseasonalized 25(OH)D <50 nmol/L; n=150)
Variable
Mean (SD)
Change From Baseline, Vitamin D
Minus PlaceboVitamin D Group (n=71) Placebo Group (n=79)
Baseline Follow-up Baseline Follow-up Mean (95% CI) P Value
Pulse rate, beats/min 62.9 (10.9) 65.7 (9.9) 66.2 (13.3) 65.4 (12.8) 3.5 (0.0 to 7.1) 0.05
Brachial SBP, mm Hg 137.4 (16.8) 125.5 (13.0) 139.4 (18.2) 132.8 (20.1) 5.3 (11.8 to 1.3) 0.11
Brachial DBP, mm Hg 78.9 (10.7) 72.8 (9.2) 80.0 (11.3) 76.6 (10.8) 2.8 (6.2 to 0.7) 0.12
Aortic SBP, mm Hg 139.8 (18.5) 127.1 (14.1) 141.1 (18.6) 136.0 (21.4) 7.5 (14.4 to 0.6) 0.03
Aortic DBP, mm Hg 72.2 (6.4) 68.9 (5.5) 73.2 (7.0) 71.3 (6.5) 1.3 (3.7 to 1.0) 0.25
Augmentation index, % 29.7 (13.6) 22.9 (8.7) 29.1 (13.7) 28.1 (14.5) 5.7 (10.8 to 0.6) 0.03
Pulse wave velocity, m/s 9.2 (1.8) 8.9 (1.5) 9.2 (1.9) 9.3 (2.0) 0.3 (0.6 to 0.1) 0.02
Peak reservoir pressure, mm Hg 125.2 (18.0) 112.3 (12.4) 125.2 (17.9) 120.9 (20.1) 8.6 (15.4 to 1.9) 0.01
Peak excess pressure, mm Hg 26.5 (6.8) 25.7 (8.4) 28.6 (8.7) 27.0 (7.9) 0.7 (2.8 to 4.1) 0.70
Reservoir pressure integral, mm Hg/s 93.0 (19.1) 81.2 (16.2) 89.5 (21.2) 87.5 (23.1) 9.8 (16.2 to 3.3) 0.003
Loge(excess pressure integral, mm Hg/s) 1.51 (0.39) 1.38 (0.47) 1.54 (0.42) 1.45 (0.43) 0.04 (0.22 to 0.14) 0.65
Backward pressure amplitude, mm Hg 28.7 (8.0) 23.5 (6.0) 28.4 (7.7) 26.7 (9.1) 3.6 (6.3 to 0.8) 0.01
Forward pressure amplitude, mm Hg 39.7 (8.8) 34.7 (6.3) 40.1 (8.7) 38.4 (9.9) 3.3 (6.4 to 0.2) 0.04
Loge(wave reflection index), 910
2 117.7 (34.2) 130.6 (31.3) 122.6 (41.8) 125.1 (50.2) 10.3 (29.2 to 8.6) 0.28
CI indicates conﬁdence interval; DBP, diastolic blood pressure; SBP, systolic blood pressure.
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ﬁndings could be due to chance. However, the treatment
effects were in line with observational research1,2,34 and
consistently unidirectional. In addition, if study conclusions
are based on factor analysis results only (which summarize
the individual relationships), fewer comparisons are involved.
Although our analyses were carried out in subsamples of
an RCT (Figure 1), we do not expect there to be important
imbalances in participant characteristics at baseline for
several reasons. First, the selection of our total analysis
sample from the main ViDA study was random. Second, the
selection of subgroups from the total sample would not differ
by treatment group because everyone was randomized the
same way. Third, effects of any imbalances in age, sex, and
ethnicity would have been minimized because these demo-
graphic variables were adjusted for in analyses. Fourth,
baseline imbalances can be reduced by stratifying the study
randomization by subgroup variables.47 Regarding that, strat-
ifying randomization by 25(OH)D concentration per se was not
carried out, but (1) some have proposed that this is not
required for prespeciﬁed subgroup analyses (eg, our study),48
and (2) its effect on reducing imbalances in subgroups would
have been partially captured because we stratiﬁed random-
ization by age and ethnicity, which predict 25(OH)D.49 Fifth,
imbalances are more inﬂuential with small sample sizes
(smaller than ours).47,48 Finally, the above points are reﬂected
in the important ﬁnding that characteristics at baseline were
similar between the treatment groups (Table 1).
In summary, monthly high-dose vitamin D supplementation
for just slightly >1 year, which increased serum 25(OH)D
concentration by >50 nmol/L with respect to placebo, had
little effect on BP parameters in the total sample. In the
vitamin D–deﬁcient sample, however, this supplementation
did not signiﬁcantly change brachial BP but had clinically
relevant, beneﬁcial effects on central BP parameters. RCTs (of
adequate statistical power) are needed to conﬁrm whether
these effects translate into improvements in cardiovascular
morbidity and mortality.
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Table S1. Antihypertensive medication regimens in the total sample; n=5171 
Antihypertensive regimen n 
Vitamin D group  Placebo group 
Baseline Follow-up  Baseline Follow-up 
0 drugs 160 154  171 167 
1 drug 45 48  32 36 
ACEI 22 17  15 14 
αB 1 4  0 1 
ARB 4 5  5 4 
βB 5 4  4 6 
CCB 7 11  6 8 
D 6 7  2 3 
2 drugs 31 36  36 32 
ACEI + αB 0 0  1 2 
ACEI + ARB 0 1  0 0 
ACEI + βB 4 5  7 6 
ACEI + CCB 2 5  6 5 
ACEI + D 10 12  10 9 
αB + ARB 0 1  0 0 
αB + βB 1 0  0 0 
αB + CCB 1 0  0 0 
ARB + βB 1 2  2 0 
ARB + CCB 0 1  1 1 
ARB + D 2 1  0 0 
βB + CCB 3 2  2 3 
βB + D 3 2  5 4 
CCB + D 4 4  2 2 
3 drugs 17 14  19 19 
ACEI + αB + βB 1 2  1 2 
ACEI + αB + CCB 1 1  1 1 
ACEI + ARB + D 0 0  1 0 
ACEI + βB + CCB 2 1  1 0 
ACEI + βB + D 3 2  4 4 
ACEI + CCB + D 5 5  5 5 
αB + ARB + βB 1 0  0 1 
αB + βB + CCB 1 1  0 0 
αB + CCB + D 0 0  1 1 
ARB + βB + CCB 2 1  0 0 
ARB + βB + D 0 0  2 3 
ARB + CCB + D 0 0  1 2 
βB + CCB + D 1 1  2 0 
4 drugs 2 3  3 7 
ACEI + αB + βB + CCB 0 1  0 0 
ACEI + αB + CCB + D 1 2  1 1 
ACEI + βB + CCB + D 1 0  0 2 
αB + ARB + βB + D 0 0  0 1 
αB + ARB + CCB + D 0 0  1 2 
ARB + βB + CCB + D 0 0  1 1 
5 drugs 1 1  0 0 
ACEI + αB + βB + CCB + D 1 1  0 0 
All drugs 96 102  90 94 
ACE=ACE inhibitor; αB=Alpha blocker; ARB=Angiotensin receptor blocker; βB=Beta blocker; 
CCB=Calcium channel blocker; D=Diuretic. 
Table S2. Antihypertensive medication regimens in the vitamin D-deficient sample; n=1501 
Antihypertensive regimen n 
Vitamin D group  Placebo group 
Baseline Follow-up  Baseline Follow-up 
0 drugs 43 40  39 35 
1 drug 15 13  11 19 
ACEI 7 5  5 8 
αB 1 1  0 0 
ARB 0 1  1 2 
βB 2 1  1 3 
CCB 2 3  3 5 
D 3 2  1 1 
2 drugs 7 12  18 16 
ACEI + αB 0 0  0 0 
ACEI + ARB 0 0  0 0 
ACEI + βB 0 1  2 2 
ACEI + CCB 0 3  5 4 
ACEI + D 2 3  7 5 
αB + ARB 0 0  0 0 
αB + βB 0 0  0 0 
αB + CCB 1 0  0 0 
ARB + βB 0 1  0 0 
ARB + CCB 0 1  1 1 
ARB + D 1 1  0 0 
βB + CCB 1 0  0 1 
βB + D 1 1  2 2 
CCB + D 1 1  1 1 
3 drugs 6 5  8 6 
ACEI + αB + βB 0 0  0 1 
ACEI + αB + CCB 0 0  1 1 
ACEI + ARB + D 0 0  0 0 
ACEI + βB + CCB 1 0  0 0 
ACEI + βB + D 1 1  3 1 
ACEI + CCB + D 2 3  1 1 
αB + ARB + βB 1 0  0 0 
αB + βB + CCB 1 1  0 0 
αB + CCB + D 0 0  0 0 
ARB + βB + CCB 0 0  0 0 
ARB + βB + D 0 0  0 1 
ARB + CCB + D 0 0  1 1 
βB + CCB + D 0 0  2 0 
4 drugs 0 1  3 3 
ACEI + αB + βB + CCB 0 1  0 0 
ACEI + αB + CCB + D 0 0  1 1 
ACEI + βB + CCB + D 0 0  0 1 
αB + ARB + βB + D 0 0  0 0 
αB + ARB + CCB + D 0 0  1 1 
ARB + βB + CCB + D 0 0  1 0 
5 drugs 0 0  0 0 
ACEI + αB + βB + CCB + D 0 0  0 0 
All drugs 28 31  40 44 
ACE=ACE inhibitor; αB=Alpha blocker; ARB=Angiotensin receptor blocker; βB=Beta blocker; 
CCB=Calcium channel blocker; D=Diuretic.
Table S3. Eigenvalues of the correlation matrix and loadings in the factor analysis (varimax 
solution) for change (follow-up minus baseline) in arterial waveform parameters among those 
with baseline vitamin D deficiency (deseasonalised 25(OH) <50 nmol/L) 
  Factor* 
Factor 1 Factor 2 Factor 3 Factor 4 
Eigenvalues 
of the matrix 
Eigenvalue 7.422 2.361 1.651 1.093 
Proportion of total variance 0.530 0.169 0.118 0.078 
      
 Arterial waveform parameter     
Loading 
(correlation 
coefficient) 
Pulse rate 0.019 -0.930 -0.093 0.032 
Brachial SBP 0.949 0.118 0.182 0.129 
Brachial DBP 0.830 -0.023 -0.064 0.038 
Aortic SBP 0.930 0.197 0.245 0.121 
Aortic DBP 0.911 -0.196 -0.047 0.049 
Augmentation index 0.058 0.768 0.135 0.187 
Pulse wave velocity 0.926 0.142 0.219 -0.111 
Peak reservoir pressure 0.941 0.265 -0.062 0.123 
Peak excess pressure 0.123 -0.001 0.976 -0.049 
Reservoir pressure integral 0.565 0.770 0.031 0.105 
loge(excess pressure integral 0.115 0.262 0.919 0.119 
Backward pressure amplitude 0.680 0.412 0.281 0.443 
Forward pressure amplitude 0.812 0.248 0.337 -0.207 
loge(wave reflection index) 0.043 0.137 0.018 0.971 
*Factors>0.3 are in bold, which indicates that the variable can be considered a significant 
constituent of that factor. 
Table S4. Changes (follow-up minus baseline) in factor analysis variables (adjusted for age, 
sex and ethnicity) by treatment group among those with baseline vitamin D deficiency 
(deseasonalised 25(OH) <50 nmol/L) 
Factor* Mean (standard deviation) 
change from baseline 
 Change from baseline, 
vitamin D minus placebo 
Vitamin D group 
(n=71) 
Placebo group 
(n=79) 
 Mean 
(95% confidence interval) 
P-value† 
Factor 1 -0.30 (1.00) 0.22 (1.00)  -0.52 (-0.94, -0.11) 0.01 
Factor 2 -0.35 (1.00) 0.10 (1.00)  -0.45 (-0.87, -0.04) 0.03 
Factor 3 0.01 (1.00) -0.24 (1.00)  0.25 (-0.16, 0.67) 0.23 
Factor 4 0.02 (1.00) 0.11 (1.00)  -0.09 (-0.50, 0.33) 0.67 
*Described in Table S3. 
†Analysis of covariance. 
 
Table S5. Arterial function measures at baseline and follow-up (adjusted for age, sex and ethnicity) by treatment group among those without 
baseline vitamin D deficiency (deseasonalized 25(OH) ≥50 nmol/L); n=367 
Variable Mean (standard deviation)  Change from baseline, 
vitamin D minus placebo Vitamin D group 
(n=185) 
 Placebo group 
(n=182) 
 
Baseline Follow-up  Baseline Follow-up  Mean (95% CI) P-value 
Pulse rate (beats/minute) 63.2 (9.6) 66.0 (9.4)  63.2 (9.5) 66.2 (11.4)  -0.1 (-2.0, 1.8) 0.89 
Brachial SBP (mmHg) 138.9 (19.0) 131.0 (16.9)  138.1 (16.0) 131.3 (18.3)  -1.1 (-4.5, 2.4) 0.54 
Brachial DBP (mmHg) 78.4 (10.5) 74.1 (10.1)  78.4 (8.9) 74.2 (9.4)  -0.2 (-2.1, 1.7) 0.85 
Aortic SBP (mmHg) 141.1 (18.4) 133.3 (16.7)  140.1 (17.4) 132.7 (19.5)  -0.4 (-3.9, 3.1) 0.82 
Aortic DBP (mmHg) 72.2 (6.7) 70.0 (6.3)  72.1 (5.4) 70.0 (5.9)  -0.2 (-1.4, 1.1) 0.79 
Augmentation index (%) 31.5 (11.5) 29.4 (11.6)  31.6 (12.8) 27.6 (11.8)  2.0 (-0.8, 4.7) 0.16 
Pulse wave velocity (m/s) 9.4 (1.6) 9.3 (1.6)  9.4 (1.7) 9.3 (1.8)  -0.0 (-0.2, 0.1) 0.81 
Peak reservoir pressure (mmHg) 124.9 (17.7) 118.8 (15.7)  125.0 (15.7) 118.6 (17.6)  0.2 (-3.2, 3.7) 0.90 
Peak excess pressure (mmHg) 29.0 (8.8) 25.6 (7.8)  27.6 (8.4) 25.4 (8.5)  -1.2 (-3.2, 0.8) 0.23 
Reservoir pressure integral (mmHg.s) 91.7 (18.0) 83.2 (16.8)  92.2 (20.8) 84.1 (20.9)  -0.2 (-4.1, 3.6) 0.91 
loge(excess pressure integral (mmHg.s)) 1.59 (0.38) 1.40 (0.41)  1.53 (0.43) 1.35 (0.43)  -0.01 (-0.11, 0.08) 0.77 
Backward pressure amplitude (mmHg) 29.0 (7.1) 26.2 (6.4)  29.0 (7.4) 26.0 (7.9)  0.2 (-1.2, 1.6) 0.77 
Forward pressure amplitude (mmHg) 40.3 (8.2) 37.6 (8.2)  39.5 (8.4) 37.3 (9.5)  -0.5 (-2.3, 1.3) 0.58 
loge(wave reflection index) (× 10
-2) -119.3 (35.0) -120.2 (28.2)  -113.0 (33.1) -122.5 (27.3)  8.7 (-0.0, 17.5) 0.05 
SBP=systolic blood pressure; DBP=diastolic blood pressure. 
 
Table S6. Correlations of deseasonalized 25(OH)D concentration (baseline and change*) 
with changes* in arterial function measures in the vitamin D group 
Variable Correlation coefficient (95% confidence interval)† 
Baseline 25(OH)‡ Change in 25(OH)§ 
Pulse rate -0.03 (-0.28, 0.21) 0.17 (-0.00, 0.33) 
Brachial SBP 0.15 (-0.03, 0.34) -0.23 (-0.43, 0.01) 
Brachial DBP 0.18 (-0.02, 0.36) -0.20 (-0.39, 0.02) 
Aortic SBP 0.21 (0.01, 0.42) -0.25 (-0.42, -0.02) 
Aortic DBP 0.11 (-0.06, 0.28) -0.13 (-0.33, 0.10) 
Augmentation index 0.18 (0.00, 0.34) -0.23 (-0.39, -0.06) 
Pulse wave velocity 0.22 (0.02, 0.40) -0.29 (-0.46, -0.08) 
Peak reservoir pressure 0.24 (0.07, 0.42) -0.31 (-0.48, -0.09) 
Peak excess pressure -0.12 (-0.32, 0.12) 0.17 (-0.04, 0.35) 
Reservoir pressure integral 0.08 (-0.12, 0.29) -0.29 (-0.44, -0.11) 
loge(excess pressure integral -0.07 (-0.30, 0.17) 0.10 (-0.09, 0.28) 
Backward pressure amplitude 0.18 (-0.05, 0.42) -0.28 (-0.45, -0.06) 
Forward pressure amplitude 0.23 (0.02, 0.44) -0.28 (-0.43, -0.09) 
loge(wave reflection index) 0.06 (-0.18, 0.29) -0.11 (-0.31, 0.10) 
SBP=systolic blood pressure; DBP=diastolic blood pressure. 
*Follow-up minus baseline. 
†Adjusted for age, sex and ethnicity. 
‡Among those with baseline deseasonalized 25(OH)<65 nmol/L. 
§Among those with baseline deseasonalized 25(OH)<50 nmol/L (vitamin D deficiency). 
 
